Connor, Clark & Lunn Investment Management Ltd. Syndax Pharmaceuticals Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$20.64 - $26.24 $521,779 - $663,347	-25,280 Reduced 70.59%	10,532 $268,000
Q3 2022 Nov 10, 2022	BUY	$18.51 - $24.79 $662,880 - $887,779	35,812 New	35,812 $861,000
Q4 2021 Feb 10, 2022	SELL	$15.23 - $22.47 $175,601 - $259,079	-11,530 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$13.87 - $19.8 $159,921 - $228,294	11,530 New	11,530 $220,000

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

89.9M

Call Options Held

1.01M

Put Options Held

692K

Black Rock Inc. New York, NY

7.91M
Shares

$112 Million
0.0% of portfolio
Kynam Capital Management, LP Princeton, NJ

5.84M
Shares

$82.8 Million
9.23% of portfolio
Wellington Management Group LLP Boston, MA

4.99M
Shares

$70.7 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

4.89M
Shares

$69.2 Million
0.0% of portfolio
Eversept Partners, LP New York, NY

4.11M
Shares

$58.2 Million
6.25% of portfolio

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $802M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account